LLY vs RMD
By Alex · Tickerpine
Eli Lilly and Company vs ResMed Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | RMD |
|---|---|---|
| Price | $1,443.50 | $239.53 |
| Market cap | $1.29T | $33.69B |
| P/E ratio | 46.9 | 21.8 |
| ROE | 86.02% | 26.40% |
| Profit margin | 31.90% | 27.79% |
| Revenue growth | 38.60% | 5.90% |
| Dividend yield | 0.48% | 1.10% |
| Beta | 0.39 | 0.76 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs RMD in plain English
- LLY is the bigger company — about 38.2× the market cap of RMD.
- RMD is cheaper on earnings (P/E 21.8 vs 46.9).
- LLY earns a higher return on equity (86% vs 26%).
- LLY is growing revenue faster (39% vs 6%).
- RMD has the higher dividend yield (1.10% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
RMD return calculator
See what $1,000 in ResMed Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.